T1	intervention 12 38	everolimus with exemestane
T2	control 46 62	exemestane alone
T3	ethinicity 66 71	Asian
T4	eligibility 72 140	patients with HER2-negative, hormone-receptor-positive breast cancer
T6	outcome-Measure 706 737	progression-free survival (PFS)
T8	total-participants 839 842	143
T9	intervention-participants 859 861	98
T10	control-participants 885 887	45
T5	control 664 683	placebo (PBO) + EXE
T11	outcome 956 966	median PFS
T14	outcome 1046 1056	Median PFS
T20	iv-cont-median 1198 1202	8.48
T21	cv-cont-median 1210 1221	4.14 months
T22	iv-cont-median 1241 1245	7.33
T23	cv-cont-median 1253 1264	2.83 months
T25	outcome 1280 1301	in non-Asian patients
T28	outcome 1482 1517	Grade 1/2 interstitial lung disease
T29	outcome 1562 1577	Quality of life
T30	ethinicity 562 571	non-Asian
T12	outcome 1141 1151	Median PFS
T13	outcome 1319 1343	grade 3/4 adverse events
T7	outcome-Measure 768 784	overall survival
T15	outcome-Measure 786 799	response rate
T16	outcome-Measure 801 822	clinical benefit rate
T17	outcome-Measure 828 834	safety
